RLMD

+ Watchlist + Portfolio

Relmada Therapeutics, Inc.

Regulated industry Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.66
52-Week Range: $1.80 – $8.00
Market Cap: $384.01M
P/E (TTM): —
EPS (TTM): -0.91
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.86
PEG Ratio: —
Return on Equity: -55.66%
Return on Assets: -32.39%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 29.52
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-23.65M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $166.28M

RLMD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$113.32M	$54.81M	$46.18M	$26.88M
Selling, General & Admin	$47.93M	$48.89M	$37.72M	$32.22M
Operating Expenses	$161.25M	$103.70M	$83.89M	$59.10M
Operating Income	-$161.25M	-$103.70M	-$83.89M	-$59.10M
EBITDA	-$161.25M	-$103.70M	-$83.89M	-$59.10M
Pretax Income	-$157.04M	-$98.79M	-$79.98M	-$57.39M
Net Income	-$157.04M	-$98.79M	-$79.98M	-$57.39M
Diluted EPS	-5.30	-3.28	-2.65	-1.45
Diluted Shares	29.63M	30.10M	30.16M	39.48M

RLMD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.40M	$4.09M	$3.86M	$3.50M
Receivables	$512.43K	$0.00	—	—
Current Assets	$152.87M	$97.51M	$45.80M	$93.98M
Total Assets	$152.91M	$97.55M	$45.82M	$94.00M
Current Liabilities	$12.47M	$12.19M	$10.29M	$6.43M
Total Liabilities	$12.47M	$12.19M	$10.30M	$7.49M
Retained Earnings	-$462.11M	-$560.90M	-$640.88M	-$698.27M
Shareholders' Equity	$140.44M	$85.36M	$35.52M	$86.51M
Working Capital	$140.40M	$85.31M	$35.50M	$87.55M

RLMD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$103.80M	-$51.66M	-$51.76M	-$45.79M
Free Cash Flow	-$103.80M	-$51.66M	-$51.76M	-$45.79M
Depreciation & Amortisation	$0.00	—	—	—
Stock-Based Compensation	$44.19M	$43.81M	$30.19M	$14.96M
Investing Cash Flow	$19.73M	$50.45M	$51.56M	-$48.14M
Financing Cash Flow	$45.02M	-$98.46K	-$40.34K	$93.56M
Net Change in Cash	-$39.05M	-$1.30M	-$234.54K	-$360.49K

RLMD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$11.95M	$2.82M	$4.04M	$8.07M	$8.09M	$8.39M
Selling, General & Admin	$6.27M	$7.40M	$6.29M	$12.26M	$11.37M	$6.62M
Operating Expenses	$18.22M	$10.22M	$10.33M	$20.33M	$19.46M	$15.01M
Operating Income	-$18.22M	-$10.22M	-$10.33M	-$20.33M	-$19.46M	-$15.01M
EBITDA	-$18.22M	-$10.22M	-$10.33M	-$20.33M	-$19.46M	-$15.01M
Pretax Income	-$17.56M	-$9.87M	-$10.09M	-$19.87M	-$19.05M	-$12.91M
Net Income	-$17.56M	-$9.87M	-$10.09M	-$19.87M	-$19.05M	-$12.91M
Diluted EPS	-0.58	-0.30	-0.30	—	-0.22	-0.11
Diluted Shares	30.41M	33.19M	33.19M	—	86.60M	112.38M

RLMD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$1.15M	$1.35M	$1.38M	$3.50M	$9.78M	$11.33M
Receivables	—	—	—	—	—	$10.91K
Current Assets	$27.66M	$21.09M	$14.85M	$93.98M	$235.34M	$219.04M
Total Assets	$27.68M	$21.12M	$14.88M	$94.00M	$235.36M	$219.06M
Current Liabilities	$5.23M	$5.13M	$5.19M	$6.43M	$12.89M	$7.42M
Total Liabilities	$5.24M	$5.17M	$5.41M	$7.49M	$16.63M	$12.50M
Retained Earnings	-$658.44M	-$668.31M	-$678.40M	-$698.27M	-$717.32M	-$730.23M
Shareholders' Equity	$22.44M	$15.95M	$9.47M	$86.51M	$218.73M	$206.56M
Working Capital	$22.43M	$15.96M	$9.66M	$87.55M	$222.45M	$211.62M

RLMD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$18.07M	-$6.40M	-$6.72M	-$14.60M	-$15.07M	-$9.61M
Free Cash Flow	-$18.07M	-$6.40M	-$6.72M	-$14.60M	-$15.07M	-$9.61M
Stock-Based Compensation	$3.58M	$3.47M	$4.70M	$3.21M	$3.63M	$2.24M
Investing Cash Flow	$15.36M	$6.68M	$6.75M	-$76.93M	-$135.23M	$17.59M
Financing Cash Flow	$0.00	-$73.02K	$0.00	$93.64M	$156.57M	-$6.42M
Net Change in Cash	-$2.71M	$203.65K	$31.13K	$2.11M	$6.28M	$1.56M

Market Snapshot

About

Relmada Therapeutics is a clinical-stage biotechnology company developing novel medicines for the treatment of central nervous system diseases. The company is focused on developing esmethadone, a new chemical entity targeting treatment-resistant depression and other psychiatric conditions. Relmada uses its expertise in opioid receptor pharmacology to create non-addictive therapeutic candidates.